Ratings Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Market Closed - Nyse Other stock markets 01:30:01 27/04/2024 am IST			5-day change	1st Jan Change
8.71 ^USD	+1.04%		+0.23%	+8.60%

25/04	Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	MT
25/04	Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company's attractive earnings multiples are brought to light by a P/E ratio at 13.25 for the current year.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company sustains low margins.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BAUSCH HEALTH COMPANIES INC.	+8.60%	3.19B	C+
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes